Citations

Clear

813 citation(s) found for "He, Helen".

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Rambau, Peter , Vierkant, Robert A. , Intermaggio, Maria P., Kelemen, Linda E. , Goodman, Marc T. , Herpel, Esther , Kommoss, Stefan , Jimenez‐Liñan, Mercedes , Menon, Usha , Polo, Susanna Hernando, Reis, Francisco José Cândido dos , Gayther, Simon A. , Sharma, Raghwa , Harnett, Paul R. , Hatfield, Emma, Andrade, Jurandyr Moreira de , Nelson, Gregg , Steed, Helen , Schildkraut, Joellen M. , Carney, Micheal E, Høgdall, Estrid , Whittemore, Alice S. , Widschwendter, Martin , Kennedy, Catherine J. , Armasu, Sebastian M. , Daley, Frances , Coulson, Penny , Jones, Michael E. , Anglesio, Michael S. , Chow, Christine , Fazio, Anna de , García‐Closas, Montserrat , Huzarski, Tomasz , Jensen, Allan , Lubiński, Jan , Oszurek, Oleg, Benı́tez, Javier , Mina, Fady , Staebler, Annette , Taran, Florin‐Andrei , Pasternak, J , Talhouk, Aline , Rossing, Mary Anne, Hendley, Joy , Group, AOCS, Fereday, Sián , Ness, Roberta B., Sieh, Weiva , El‐Bahrawy, Mona , Lester, Jenny , Sinn, Hans‐Peter , Fasching, Peter A. , Chang‐Claude, Jenny , Moysich, Kirsten B. , Bowtell, David D.L. , Luk, Hugh, Shah, Mitul , Jung, Audrey , Alsop, Jennifer , Thompson, Pamela J., Swerdlow, Anthony J. , Karpinskyj, Chloe , García, María J. , Deen, Susha, Palacios, José , Koziak, Jennifer M. , Goode, Ellen L. , Huntsman, David G. , Ramus, Susan J. , Köbel, Martin , DeFazio, Anna , Köbel, Martin , Ramus, Susan J , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Swerdlow, Anthony J , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Anglesio, Michael S , Jones, Michael E , Sieh, Weiva , García-Closas, Montserrat , Benitez, Javier , Høgdall, Estrid , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Fereday, Sian , Lubinski, Jan , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Steed, Helen , Goodman, Marc T , Pharoah, Paul D.P. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Doherty, Jennifer A. , Larson, Melissa C. , Hatfield, Emma, Wang, Frances M. , Wang, Qin , Wang, Chen , Brucker, Sara Yvonne , Cybulski, Cezary , Harris, Holly R. , Hartkopf, Andreas D , Group, AOCS, Edwards, Todd , Modugno, Francesmary , Winham, Stacey J. , Kjær, Susanne K. , Gronwald, Jacek , Hernandez, Brenda Y. , Behrens, Sabine , Ghatage, Prafull , Alsop, Kathryn , García-Donás, Jesús , Cazorla, Alicia , Wilkens, Lynne R. , Berchuck, Andrew , Brenton, James D. , Cook, Linda S.

Mayo Clinic

The Journal of Pathology: Clinical Research | July 30, 2018 | Volume: 4 | Issue: 4 | Pages: 250-261

10.1002/cjp2.109 | PMID 30062862 Get It

AbstractWe aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical‐grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis‐associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while absence was associated with shorter OS in low‐grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype‐specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low‐grade serous carcinoma justifies CDK4 inhibition.
Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes
Hu, Chunling , LaDuca, Holly , Lilyquist, Jenna , Thomas, Abigail, Davis, Brigette Tippin, Black, Mary Helen , Pesaran, Tina , Goldgar, David E. , Dolinsky, Jill S. , Shimelis, Hermela , Polley, Eric C. , Hart, Steven N. , Na, Jie , Lee, Kun Y. , Hu, Chunling , Couch, Fergus J.

Mayo Clinic

JCO Precision Oncology | July 25, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-28

10.1200/po.17.00291 | PMID 31497750 Get It

Purpose The relevance of inherited pathogenic mutations in cancer predisposition genes in pancreatic cancer is not well understood. We aimed to assess the characteristics of patients with pancreatic cancer referred for hereditary cancer genetic testing and to estimate the risk of pancreatic cancer associated with mutations in panel-based cancer predisposition genes in this high-risk population. Methods Patients with pancreatic cancer (N = 1,652) were identified from a 140,000-patient cohort undergoing multigene panel testing of predisposition genes between March 2012 and June 2016. Gene-level mutation frequencies relative to Exome Aggregation Consortium and Genome Aggregation Database reference controls were assessed. Results The frequency of germline cancer predisposition gene mutations among patients with pancreatic cancer was 20.73%. Mutations in ATM, BRCA2, CDKN2A, MSH2, MSH6, PALB2, and TP53 were associated with high pancreatic cancer risk (odds ratio, > 5), and mutations in BRCA1 were associated with moderate risk (odds ratio, > 2). In a logistic regression model adjusted for age at diagnosis and family history of cancer, ATM and BRCA2 mutations were associated with personal history of breast or pancreatic cancer, whereas PALB2 mutations were associated with family history of breast or pancreatic cancer. Conclusion These findings provide insight into the spectrum of mutations expected in patients with pancreatic cancer referred for cancer predisposition testing. Mutations in eight genes confer high or moderate risk of pancreatic cancer and may prove useful for risk assessment for pancreatic and other cancers. Family and personal histories of breast cancer are strong predictors of germline mutations.
Amyotrophic lateral sclerosis–specific quality of life–short form (ALSSQOL‐SF): A brief, reliable, and valid version of the ALSSQOL‐R
Felgoise, Stephanie H. , Feinberg, Richard A. , Stephens, Helen , Clawson, Lora , Elman, Lauren , Goutman, Stephen A. , McCluskey, Leo, Russell, James W. , Tiryaki, Ezgi , Weiss, Michael D. , Simmons, Zachary , Boylan, Kevin, Goutman, Stephen A , Simmons, Zachary , Barkhaus, Paul E. , Boylan, Khrista , Caress, James B.

Mayo Clinic

Muscle & Nerve | July 20, 2018 | Volume: 58 | Issue: 5 | Pages: 646-654

10.1002/mus.26203 | PMID 30028537 Get It

ABSTRACT Introduction: The Amyotrophic Lateral Sclerosis (ALS)‐Specific Quality of Life instrument and its revised version (ALSSQOL and ALSSQOL‐R) have strong psychometric properties, and have demonstrated research and clinical utility. In this study we aimed to develop a short form (ALSSQOL‐SF) suitable for limited clinic time and patient stamina. Methods: The ALSSQOL‐SF was created using Item Response Theory and confirmatory factor analysis on 389 patients. A cross‐validation sample of 162 patients assessed convergent, divergent, and construct validity of the ALSSQOL‐SF compared with psychosocial and physical functioning measures. Results: The ALSSQOL‐SF consisted of 20 items. Compared with the ALSSQOL‐R, optimal precision was retained, and completion time was reduced from 15–25 minutes to 2–4 minutes. Psychometric properties for the ALSSQOL‐SF and its subscales were strong. Discussion: The ALSSQOL‐SF is a disease‐specific global QOL instrument that has a short administration time suitable for clinical use, and can provide clinically useful, valid information about persons with ALS. Muscle Nerve 58: 646–654, 2018
AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State‐of‐the‐art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary‐like nuclear features
Nikiforov, Yuri E. , Terris, Davis, Seethala, Raja R. , Sabra, Mona M. , McIver, Bryan, Bernet, Victor , Harrell, R. Mack, Busaidy, Naifa L. , Sadow, Peter M. , Shindo, Maisie L., Nikiforov, Yuri , Terris, Davis , Bernet, Victor J, Ferris, Robert L. , Ridge, John Andrew , Angelos, Peter , Duh, Quan‐Yang , Wong, Richard J. , Fagin, James A. , Cibas, Edmund S. , Faquin, William C , Baloch, Zubair , Orloff, Lisa A. , Davies, Louise , Randolph, Gregory William

Mayo Clinic

Head & Neck | June 27, 2018 | Volume: 40 | Issue: 9 | Pages: 1881-1888

10.1002/hed.25141 | PMID 29947030 Get It

AbstractThe newly introduced pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP) will result in less bilateral thyroid surgery as well as deescalation in T4 suppressive and radioactive iodine treatment. Although, NIFTP is a nonmalignant lesion that has nuclear features of some papillary malignancies, the challenge for the surgeon is to identify a lesion as possibly NIFTP before the pathologic diagnosis. NIFTP, due to its reduction of overall rates of malignancy, will result in the initial surgical pendulum swinging toward lobectomy instead of initial total thyroidectomy. This American Head and Neck Society endocrine section consensus statement is intended to inform preoperative evaluation to attempt to identify those patients whose final pathology report may ultimately harbor NIFTP and can be offered a conservative surgical plan to assist in cost‐effective, optimal management of patients with NIFTP.
Value-Added Activities in Medical Education: A Multisite Survey of First- and Second-Year Medical Students’ Perceptions and Factors Influencing Their Potential Engagement
Starr, Stephanie R. , Gonzalo, Jed D. , George, Paul , Miller, Bonnie M. , Morgan, Helen , Hoffman, Ari, Baxley, Elizabeth G., Allen, Bradley L. , Fancher, Tonya L. , Mandrekar, Jay , Skochelak, Susan E., Reed, Darcy A. , Leep Hunderfund, Andrea N, Fancher, Tonya L , Hunderfund, Andrea N. Leep , Dyrbye, Liselotte N.

Mayo Clinic

Academic Medicine | May 23, 2018 | Volume: 93 | Issue: 10 | Pages: 1560-1568

10.1097/acm.0000000000002299 | PMID 29794526 Get It

Purpose To describe attitudes of first- and second-year U.S. medical students toward value-added medical education, assess their self-reported desire to participate in value-added activities, and identify potentially modifiable factors influencing their engagement. Method The authors conducted a cross-sectional survey of first- and second-year students at nine U.S. medical schools in 2017. Survey items measured students’ attitudes toward value-added medical education (n = 7), desire to participate in value-added activities (n = 20), and factors influencing potential engagement (n = 18). Results Of 2,670 students invited to participate, 1,372 (51%) responded. Seventy-six percent (1,043/1,368) moderately or strongly agreed they should make meaningful contributions to patient care. Students’ desire to participate was highest for patient care activities approximating those traditionally performed by physicians, followed by systems improvement activities and lowest for activities not typically performed by physicians. Factors increasing desire to participate included opportunities to interact with practicing physicians (1,182/1,244; 95%), patients (1,177/1,246; 95%), and residents or fellows (1,166/1,246; 94%). Factors decreasing desire to participate included making changes to the health care system (365/1,227; 30%), interacting with patients via phone or electronic communication (410/1,243; 33%), and lack of curricular time (634/1,233; 51%). Conclusions First- and second-year medical students agree they should add value to patient care, but their desire to participate in value-added activities varies depending on the nature of the tasks. Medical schools may be able to increase students’ desire to participate by enabling face-to-face interactions with patients, embedding students in health care teams, and providing dedicated curricular time.
Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or Dementia
Roberts, Rosebud O., Roberts, Lewis A., Geda, Yonas E. , Cha, Ruth H., O’Connor, Helen M. , Petersen, Ronald C. , Geda, Yonas E , Cha, Ruth H., Pankratz, V. Shane , Knopman, David S.

Mayo Clinic

Journal of Alzheimer's Disease | May 16, 2018 | Volume: 32 | Issue: 2 | Pages: 329-339

10.3233/jad-2012-120862 | PMID 22810099 Get It

Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group
Kossoff, Eric H. , Zupec‐Kania, Beth, Auvin, Stéphane , Ballaban‐Gil, Karen , Bergqvist, Anna, Blackford, Robyn, Buchhalter, Jeffrey , Caraballo, Roberto , Cross, J. Helen , Dahlin, Maria , Donner, Elizabeth , Güzel, Orkide, Jehle, Rana, Klepper, Joerg , Kang, Hoon‐Chul , Lambrechts, Danielle A.J.E. , Liu, Y.M. Christiana, Nathan, Janak , Pfeifer, Heidi H., Rho, Jong M. , Scheffer, Ingrid E. , Sharma, Suvasini , Stafstrom, Carl E. , Thiele, Elizabeth A. , Turner, Zahava , Vaccarezza, María, Louw, Elles van der , Friends, Matthew's, Caraballo, Roberto H , Wirrell, Elaine C., Auvin, Stéphane , Cross, Helen J , Scheffer, Ingrid E , Nordli, Douglas R. , Veggiotti, Pierangelo , Wheless, James W. , Wirrell, Elaine , Friends, Matthew's

Mayo Clinic

Epilepsia Open | April 25, 2018 | Volume: 3 | Issue: 2 | Pages: 175-192

10.1002/epi4.12225 | PMID 29881797 Get It

Summary Ketogenic dietary therapies ( KDTs ) are established, effective nonpharmacologic treatments for intractable childhood epilepsy. For many years KDTs were implemented differently throughout the world due to lack of consistent protocols. In 2009, an expert consensus guideline for the management of children on KDT was published, focusing on topics of patient selection, pre‐ KDT counseling and evaluation, diet choice and attributes, implementation, supplementation, follow‐up, side events, and KDT discontinuation. It has been helpful in outlining a state‐of‐the‐art protocol, standardizing KDT for multicenter clinical trials, and identifying areas of controversy and uncertainty for future research. Now one decade later, the organizers and authors of this guideline present a revised version with additional authors, in order to include recent research, especially regarding other dietary treatments, clarifying indications for use, side effects during initiation and ongoing use, value of supplements, and methods of KDT discontinuation. In addition, authors completed a survey of their institution's practices, which was compared to responses from the original consensus survey, to show trends in management over the last 10 years.
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma
Chakrabarti, Sakti , Paripati, Harshita, Ross, Helen J. , Yoon, Harry H. , Paripati, Harshita R, Dong, Haidong , Chakrabarti, Sakti

Mayo Clinic

The Oncologist | April 19, 2018 | Volume: 23 | Issue: 7 | Pages: 840-843

10.1634/theoncologist.2017-0561 | PMID 29674442 Get It

Abstract Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma. This report describes the exceptional response of two patients who received ramucirumab plus paclitaxel after progressive disease on pembrolizumab. This early clinical observation suggests that the sequence of administration of PD-1 blockade and chemotherapy may be important in this disease.